方法：选取本院2011-01/2012-02住院的原发性青光眼患者共78例89眼，按照数字表随机分为对照组和观察组，疗程6mo。观察治疗前后两组患者视力、视网膜平均感光度、眼压、视盘形态学的变化，以及评价疗效。

结果：两组患者治疗前后视力、眼压、视盘形态学均无明显变化，差异无统计学意义。对照组患者治疗前后视网膜平均感光度无明显变化(14.75±5.17 vs 13.48±4.69)，而治疗组患者经羟苯磺酸钙治疗，视网膜平均感光度明显改善(14.56±5.03 vs 18.9±5.77)，差异有统计学意义(P<0.05)，与对照组治疗后相比，差异亦有统计学意义(P<0.05)。 对照组视网膜平均感光度改善率、稳定率、恶化率分别为10.3%，48.7%，41.0%； 而观察组分别为64.1%，28.2%，7.7%，两组相比差异有统计学意义(P<0.05)。

结论：羟苯磺酸钙能提高青光眼患者视网膜平均光敏感度，对眼压已控制的青光眼患者有视神经保护作用。

METHODS: A total of 78 inpatients(89 eyes)with glaucoma in this hospital from January, 2011 to February, 2012 were enrolled. All patients were randomly divided into treatment group and control group with 6 months in a course. The visual acuity, visual field(mean sensibility, MS), and intraocular pressure were measured at the experiment onset and 6 months later to evaluate the clinical effect.

RESULTS: There were no statistically significant differences in the visual acuity, intraocular pressure between the two groups neither at the experiment onset nor after 6 months(P>0.05). The mean sensibility(MS)of the treatment group was obviously improved(14.56±5.03 vs 18.9±5.77, P<0.05)with statistically significant differences before and after the treatment, while the MS remained unchanged in the control group(14.75±5.17 vs 13.48±4.69). There are statistically significant difference between the treatment group and the control group. Compared to the ratio of improvement, stability, and deterioration in the control group(10.3%, 48.7%, 41.0%), the indexes were changed obviously in the treatment group(64.1%, 28.2%, 7.7%,P<0.05)with statistically significant difference between the two groups.

CONCLUSION:Calcium dobesilate can improve mean retinal sensitivity and protect the optic nerve in glaucoma patients whose intraocular pressure has been controlled.